SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN HEALTHY MALE VOLUNTEERS.

被引：0
|
作者：
Koenen, R. [1 ]
Fowler, A. [2 ]
Gupta, A. [1 ]
Hilbert, J. [3 ]
机构：
[1] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[2] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[3] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-011
引用
收藏
页码：S78 / S78
页数：1
相关论文
共 50 条
  • [1] SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN HEALTHY CHINESE AND JAPANESE MALES.
    Jang, I.
    Kim, J.
    Koenen, R.
    Gupta, A.
    Fowler, A.
    Tadayasu, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S85 - S85
  • [2] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma
    Fowler, Andy
    Koenen, Ruediger
    Hilbert, James
    Blatchford, Jon
    Kappeler, Dominik
    Benediktus, Ewald
    Wood, Chester
    Gupta, Abhya
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (11): : 1444 - 1453
  • [3] PHARMACODYNAMICS OF MULTIPLE RISING ORAL DOSES OF BI 1021958, A NOVEL CRTH2 ANTAGONIST, IN CONTROLLED ASTHMATIC PATIENTS.
    Fowler, A.
    Hilbert, J.
    Koenen, R.
    Kappeler, D.
    Wood, C.
    Gupta, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S85 - S85
  • [4] LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist
    Bateman, Eric
    Mackie, Alison
    Benediktus, Ewald
    Schepers, Carnelia
    Kim, Jiyeong Maria
    Tadayasu, Yusuke
    Lee, Ganghyuck
    Wood, Chester
    Weber, Benjamin
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [5] Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers
    Huettner, S.
    Graefe-Mody, E. U.
    Withopf, B.
    Ring, A.
    Dugi, K. A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (10): : 1171 - 1178
  • [6] Evaluation of safety, tolerability and pharmacokinetics of single escalating oral doses of DPC 333 in healthy volunteers.
    Benedek, IH
    Fossler, M
    Wetherington, J
    Mondick, J
    Davis, C
    Kornhauser, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P61 - P61
  • [7] A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects
    Gehin, Martine
    Strasser, Daniel S.
    Zisowsky, Jochen
    Farine, Herve
    Groenen, Peter M. A.
    Dingemanse, Jasper
    Sidharta, Patricia N.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (07): : 787 - 797
  • [8] PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF CTB-001 AFTER SINGLE INTRAVENOUS DOSES IN HEALTHY MALE VOLUNTEERS.
    Kim, Y.
    Choi, H.
    Noh, Y.
    Kim, M.
    Jeon, H.
    Lim, H.
    Bae, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S48 - S48
  • [9] Safety, tolerability, pharmacodynamics and pharmacokinetics of teverelix following single or repeated doses administered subcutaneously to healthy female volunteers.
    Maclean, CM
    Larsen, F
    Beglinger, C
    Piechatzek, R
    Drewe, J
    FERTILITY AND STERILITY, 2005, 84 : S352 - S353
  • [10] Multiple rising doses of oral BI 1358894 in healthy male volunteers: a phase I study investigating safety, tolerability and pharmacokinetics
    Goettel, M.
    Fuertig, R.
    Wiebe, S.
    Herich, L.
    Sharma, V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S254 - S255
12345